Literature DB >> 23061764

Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation.

Taku Kikuchi1, Takehiko Mori, Akiko Yamane, Jun Kato, Sumiko Kohashi, Shinichiro Okamoto.   

Abstract

Drug interaction between voriconazole and calcineurin inhibitors is often problematic after allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. We previously demonstrated an unpredictable inter-individual variability in the magnitude of this drug interaction; however, the route of drug administration was not taken into account. In this study, the drug interaction between voriconazole and calcineurin inhibitors was further analyzed under the condition that both agents were administered orally. Twenty adult recipients of HSCT who had already been on a steady dose of oral cyclosporine A (CsA) and were started on oral voriconazole (400 mg/d) were eligible. The changes in the concentration/dose (C/D) ratio of CsA were evaluated by comparing the trough concentrations of CsA measured before and 7-10 d after initiating voriconazole. The median C/D ratio of CsA increased significantly from 64.1 to 114.3 (ng/mL)/(mg/kg) after initiating voriconazole (p < 0.01), and the median increase was 83.0% (range, 0.3-224.7%). The plasma concentration of voriconazole did not correlate significantly with the increase of the C/D ratio (ρ = -0.18, p = 0.45). These results indicate that the magnitude of drug interaction between oral voriconazole and CsA is widely variable, and it could not be explained by the difference in the blood levels of voriconazole. Further studies are required to elucidate the mechanism for this variability.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23061764     DOI: 10.1111/ctr.12016

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

Review 1.  Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Authors:  Anna B Halpern; Gary H Lyman; Thomas J Walsh; Dimitrios P Kontoyiannis; Roland B Walter
Journal:  Blood       Date:  2015-10-26       Impact factor: 22.113

Review 2.  The importance of hypoxia and extra physiologic oxygen shock/stress for collection and processing of stem and progenitor cells to understand true physiology/pathology of these cells ex vivo.

Authors:  Hal E Broxmeyer; Heather A O'Leary; Xinxin Huang; Charlie Mantel
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Enhancing Hematopoietic Stem Cell Transplantation Efficacy by Mitigating Oxygen Shock.

Authors:  Charlie R Mantel; Heather A O'Leary; Brahmananda R Chitteti; XinXin Huang; Scott Cooper; Giao Hangoc; Nickolay Brustovetsky; Edward F Srour; Man Ryul Lee; Steven Messina-Graham; David M Haas; Nadia Falah; Reuben Kapur; Louis M Pelus; Nabeel Bardeesy; Julien Fitamant; Mircea Ivan; Kye-Seong Kim; Hal E Broxmeyer
Journal:  Cell       Date:  2015-06-11       Impact factor: 41.582

4.  Cerebral Scedosporium apiospermum infection presenting with intestinal manifestations.

Authors:  D Lin; Q Kamili; K Qurat-Ul-Ain; S Lai; D M Musher; R Hamill
Journal:  Infection       Date:  2013-02-26       Impact factor: 3.553

5.  Elevation of blood ciclosporin levels by voriconazole leading to leukoencephalopathy.

Authors:  Qu Caihong; Liu Weimin; Zhu Jieming
Journal:  J Pharmacol Pharmacother       Date:  2013-10

6.  Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients.

Authors:  Hamidreza Taghvaye Masoumi; Molouk Hadjibabaie; Mohammad Vaezi; Ardeshir Ghavamzadeh
Journal:  J Res Pharm Pract       Date:  2017 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.